Bexsero A multicomponent vaccine for prevention of meningococcal disease
Bexsero A multicomponent vaccine for prevention of meningococcal disease
复制标题
DOI：
10.4161/hv.18500
复制
发表时间：
2012-02-01
影响因子：
4.8
通讯作者：
Pajon, Rolando
中科院分区：
文献类型：
--
作者：
Gorringe, Andrew R.;Pajon, Rolando
血清群B脑膜炎球菌（MenB）疾病仍然是一个严重的公共卫生问题，对于该疾病，还没有针对广泛范围的MenB分离株有效的交叉保护性疫苗。Novartis Vaccines已经开发了一种用于预防MenB疾病的疫苗，其含有四种抗原组分：因子H结合蛋白（fHbp）、奈瑟球菌粘附素A（NadA）、奈瑟球菌肝素结合抗原（NHBA）和来自新西兰流行株的外膜囊泡（其提供PorA）。该疫苗已在欧洲提交监管审查，因此现在是审查疫苗设计、迄今为止的临床研究结果和疫苗提供的潜在毒株覆盖率的时候了。讨论疫苗长期成功的关键问题也至关重要，包括菌株覆盖率、潜在的保护持久性、对MenB菌株携带的潜在影响、逃逸突变体的可能性和成本效益。
Serogroup B meningococcal (MenB) disease remains a serious public health problem for which a cross-protective vaccine effective against a wide range of MenB isolates has not been available. Novartis Vaccines has developed a vaccine for the prevention of MenB disease that contains four antigenic components: factor H binding protein (fHbp), neisserial adhesin A (NadA), Neisserial heparin binding antigen (NHBA) and outer membrane vesicles from a New Zealand epidemic strain (which provides PorA). This vaccine has been submitted for regulatory review in Europe so it is timely to review the design of the vaccine, results to date in clinical studies and the potential strain coverage provided by the vaccine. It is also critical to discuss the key issues for the long-term success of the vaccine which include strain coverage, potential persistence of protection, potential effects on carriage of MenB strains, potential for escape mutants and cost effectiveness.